YARROW BIOSCIENCE, INC. Available-for-sale Securities, Amortized Cost Basis
YARROW BIOSCIENCE, INC. (YARW) had Available-for-sale Securities, Amortized Cost Basis of $23.23 million as of 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2020-05-11
- 2020-03-31: Available-for-sale Securities, Amortized Cost Basis $23.23M.
- 2019-12-31: Available-for-sale Securities, Amortized Cost Basis $15.66M.
- 2018-09-30: Available-for-sale Securities, Amortized Cost Basis $150.02M.
- 2018-06-30: Available-for-sale Securities, Amortized Cost Basis $160.99M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2020-03-31 | $23.23M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $15.66M 10-Q · filed 2020-05-11 |
| 2018-09-30 | $150.02M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $160.99M 10-Q · filed 2018-08-01 |
| 2017-12-31 | $61.01M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |